Comparison of efficacy and safety of 0.01% Bimatoprost and 0.1%Tacrolimus in the treatment of facial vitiligo

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20161008001

Enrollment

Registered

2016-10-08

Start date

2016-08-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

randomized facial vitiligo to apply 0.01%bimatoprost to lesion b.i.d,randomized another facial vitiligo in the same patient to apply 0.1%tacrolimus b.i.d

Experimental Drug,Active Comparator Drug

0.01% bimatoprost,0.1%protopic

Eligibility

Sex/Gender

All

Age

15 Years to 90 Years

Inclusion criteria

Inclusion criteria: - facial vitiligo patient - other affected vitiligo area less than 2% BSA

Exclusion criteria

Exclusion criteria: - apply topical steroid within 7 days - on current medication effected skin pigmentation within 2 weeks - on current treatment of vitiligo such as oral medication, NBVUB, PUVA, systemic steriod within 1 month - allergy to bimatoprost and protopic - pregnancy and breast feeding patient - underlying disease: asthma

Design outcomes

Primary

Measure	Time frame
compare efficacy of 0.01%bimatoprost to 0.1%protopic 1,2,3 month percent repigmentation and are of repigmentation	—

Secondary

Measure	Time frame
safety of 0.01%bimatoprost 1,2,3 month check list for side effect	—

Countries

Thailand

Contacts

Public ContactDuangrat Pruettivorawongse

0-2201-1211

bepruet@gmail.com0914156924

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026